Drug
Urelumab
Drug Profile
| Therapeutic Class | Monoclonal Antibodies (mAbs) |
| Drug Class | Other mAbs |
| Group | CD137 agonist mAb |
| Mechanism of Action | CD137 agonist |
Study design
RT–Drug Timing Window
Study design
RT–Drug Timing Window
Radiobiological rationale for RT–drug interaction
Immunologically synergistic (RT ↑4-1BB; agonism boosts CD8/abscopal effect) (Rodriguez-Ruiz et al. Cancer Research 2016; Martin et al. Cancer Immunology Immunotherapy 2023). The relevant theoretical added risk is immune-mediated (urelumab-associated hepatological adverse events; enhanced systemic inflammation) rather than in-field radiation side-effects.
Data on this page refer exclusively to patients treated with
Urelumab combined with SBRT, without concurrent use of
drugs from other classes.
Combination therapy data and pooled group-level evidence are available on the
CD137 agonist mAb group page.